TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03812900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea alcoholic extract
Description: Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea alcoholic extract
Description: Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea alcoholic extract
Description: Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea alcoholic extract
Description: Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)
Study: NCT02500316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
Study: NCT00729716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioCart™II
Description: A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation. Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium. Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: MF procedure will be carried out according to accepted practice. After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl. The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation. With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn. This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
Study: NCT01246895

Intervention type: DEVICE
Intervention: Microfracture with BST-CarGel

Intervention type: DEVICE
Intervention: Microfracture without BST-CarGel
Study: NCT02298348

Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: Sorafenib -100-200mg/m2/dose (dose escalation), Orally BID continuously Days 1 thru 28 Cyclophosphamide - 250 mg/m2/day IV x 5 days - day 1 thru day 5 Topotecan - 0.75 mg/m2/day IV x 5 days - day 1 thru day 5

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)

Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan
Description: 0.75mg/m2.day IV x5 days (Day 1 through Day 5 of each course)
Study: NCT01124747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-Labeled ASP1585
Description: Oral
Study: NCT02436863

Intervention type: PROCEDURE
Intervention: Surgical performance
Description: Two different surgical performances

Intervention type: PROCEDURE
Intervention: Surgical performance
Description: Two different surgical performances
Study: NCT03740269

Intervention type: OTHER
Intervention: oral health educational program
Description: poster education about the important of oral health status, different brushing technique, different tooth paste, the balanced diet, changes occur to their mouth during the puberty period
Study: NCT01026948

Intervention type: DRUG
Intervention: Dinoprostone
Description: Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.

Intervention type: DEVICE
Intervention: Monica AN 24
Description: AN24 Monica is a portable, battery powered device designed to passively monitor a pregnant mother and unborn baby. The device is attached via a suitable cable assembly which in turn attaches to 5 standard disposable electrodes placed on the abdomen of a pregnant woman and is intended for use in either the home or hospital environment.
Study: NCT03281941

Intervention type: OTHER
Group type: OTHER
Intervention: Inhaled capsaicin cough challenge

Intervention type: OTHER
Group type: OTHER
Intervention: Inhaled capsaicin cough challenge
Study: NCT00558987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discipline Video
Description: 1. The discipline video will be shown to the caregiver before the visit while they are waiting to see the doctor. The video gives specific guidance on avoiding physical discipline, setting consistent, safe and age appropriate limits.~2. A copy of the discipline video and the handout reinforcing the messages presented in the video will be given to the caregiver by the research staff to share with other caregivers.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Nutrition Video
Description: A brief educational video on nutrition information, a topic not related to discipline.
Study: NCT03970525

Intervention type: DEVICE
Intervention: Venturi pump
Description: The venturi pump makes use of the venturi effect to create a vacuum. The venturi effect creates a vacuum by the flow of a fluid, typically air, over an opening. In many phacoemulsification machines, this requires nitrogen tanks or a self-contained air compressor. The vacuum level is created within a rigid drainage cassette, to which the phaco aspiration tubing is connected. Since there is no milking of the aspiration line, the phaco tubing can be made rigid with low compliance.

Intervention type: DEVICE
Intervention: Peristaltic vacuum pump
Description: The peristaltic pump uses rollers to compress the phacoemulsification outflow tubing in a peristaltic manner, thereby creating flow and vacuum. The compression of the rollers on the tubing with the rotation of the pump physically moves fluid and creates a continuous milking action on the fluid column, The phaco machine can directly control this flow level, hence the term flow based, however, the preset vacuum level is only achieved once there is occlusion of the outflow line, typically at the phaco needle tip with cataract material.
Study: NCT01935024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Exercise Regimen
Description: All exercise regimens include a stationary bicycle.
Study: NCT00802646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline
Description: intrathecal preservative free normal saline, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl/bupivacaine/epinephrine
Description: intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
Study: NCT01655225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally. Dose of 20 to 600 mg, as determined in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally. Dose of 20 to 600 mg, as determined in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally. Dose of 20 to 600 mg, as determined in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally. Dose of 20 to 600 mg, as determined in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally. Dose of 20 to 600 mg, as determined in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally. Dose of 20 to 600 mg, as determined in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally. Dose of 20 to 600 mg, as determined in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally. Dose of 20 to 600 mg, as determined in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally. Dose of 20 to 600 mg, as determined in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 administered IV once on Day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 administered IV once on Day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Administered orally
Study: NCT01660867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% saline + oral placebo
Description: nebulized epinephrine + 3% saline + placebo =\> nebulized epinephrine + 3% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline + oral dexamethasone
Description: nebulized epinephrine + 0.9% saline + dexamethasone =\> nebulized epinephrine + 0.9% saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline + oral dexamethasone
Description: nebulized epinephrine + 0.9% saline + dexamethasone =\> nebulized epinephrine + 0.9% saline
Study: NCT02721056

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: NBTXR3, IL or IA injection + SBRT
Description: Patients will receive a single administration of NBTXR3 on day of injection, as intralesional or super selective transcatheter arterial injection activated by Stereotactic Body Radiation Therapy starting 24 hours post injection. The total radiotherapy dose will be 45 or 50 Gy, delivered as three fractions of 15 Gy or 5 fractions of 10 Gy each, over 5 to 15 days (45 or 50Gy, 15GyX3 or 10GyX5).
Study: NCT01157611

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mentoring program
Description: mentoring program group patients should register their SMBG, exercise, food intake and insulin dose on the website designed for this study and receive advices of mentors from peer group.
Study: NCT02434874

Intervention type: DEVICE
Group type: OTHER
Intervention: StimGuard Sacral Nerve Stimulator System
Description: The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimGuard Sacral Nerve Stimulator System
Description: The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
Study: NCT01676701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tabalumab Auto-Injector
Description: Administered SC by auto-injector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tabalumab Prefilled Syringe
Description: Administered SC by prefilled syringe
Study: NCT03851848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint mobilization (JM)
Description: Joint mobilization (JM) is a manual therapy to move the joint in a desired direction. It is commonly used for improving the joints' ROM and pain intensity, and to overcome joint restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR)
Description: Myofascial release (MFR) is a technique in which a slow, sustained pressure is applied to the restricted soft tissue in order to restore optimal length, reduce pain and improve function.
Study: NCT03708263

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excel V 532nm (KTP) green Laser
Description: Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHOTOLASE PLV 585 nm yellow laser
Description: Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
Study: NCT02825914

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein glycomacropeptide (CGMP)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04443647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Syntocinon nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study: NCT00810199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: tocilizumab 8 mg IV every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: tocilizumab 8 mg IV every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Approximately 15-17 mg methotrexate capsule orally once a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo matching methotrexate capsule taken orally once a week.
Study: NCT01448252

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)
Description: multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: T cell vaccination
Description: Multiple injections of autologous T cell lines reactive to 9 myelin peptides.
Study: NCT00888888

Intervention type: PROCEDURE
Intervention: Right hemicolectomy with or without primary anastomosis
Description: During open classic appendectomy (McBurney incision) the surgeon decided to convert to midline extended laparotomy to perform a right hemicolectomy
Study: NCT03374475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 20mg
Description: Participants will swallow 20 mg (2\*10 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 40mg
Description: Participants will swallow 40 mg (2\*20 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
Study: NCT04356469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical Hematopoietic Cell Transplantation
Description: TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
Study: NCT02012725

Intervention type: DRUG
Intervention: Arm 1 MRI with gadolinium
Description: Healthy volunteers will not receive gadolinium
Study: NCT02309957

Intervention type: DEVICE
Intervention: BioMatrix CRD
Study: NCT03808792

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound, CT and WB-DWI/MRI
Description: Preoperative assessment with Ultrasound, CT and WB-DWI/MRI
Study: NCT00799981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A=SpeediCath Compact 7 cm and B=POBE 10 cm
Description: Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A=SpeediCath Compact 7 cm and B=POBE 10 cm
Description: Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A=SpeediCath Compact 7 cm and B=POBE 10 cm
Description: Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A=SpeediCath Compact 7 cm and B=POBE 10 cm
Description: Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A=SpeediCath Compact 7 cm and B=POBE 10 cm
Description: Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A=SpeediCath Compact 7 cm and B=POBE 10 cm
Description: Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Study: NCT01161238

Intervention type: OTHER
Intervention: Monitored for limb volume
Description: Subjects are monitored for limb volume change using bioimpedance analysis
Study: NCT02610517

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provider Training
Description: All providers will receive an online survey about alcohol pharmacotherapy, and an on-site training on alcohol pharmacotherapy will be offered at UAB and UW. The training will cover the most commonly prescribed alcohol pharmacotherapy. Some medications (ex: Zofran) have been used clinically for alcohol pharmacotherapy but have not yet received FDA approval for this indication. Research has shown these medications are beneficial as alcohol pharmacotherapy and are more frequently used by doctors due to the more favorable side effects. Providers in this study will use their clinical judgment in prescribing alcohol medications per their normal standard of care and using any new information gained from the alcohol pharmacotherapy training.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Intervention
Description: Eligible participants will be screened using the Audit and Mini instruments that are routinely asked during regular clinic visits. Once a participant consents, they will be shown 2 computerized brief interventions (CBIs) - one after enrollment (visit 1) and one 3-6 months after enrollment (visit 2). Participants will interact with the touch-screen computer via Peedy the Parrot, a three dimensional animated character. The intervention emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. At the end of both visits, patients will complete a patient satisfaction survey with questions related to ease of use of CBI and satisfaction with program content. Providers will have the opportunity to prescribe pharmacotherapy at visit 1 and 2.
Study: NCT03821987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients enrolled in this study would receive Bu (IV)0.8mg/kg Q6hx2d,Fludarabine 30mg/m2x5d ,CTX (cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.
Study: NCT01170325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT04916717

Intervention type: OTHER
Group type: OTHER
Intervention: Counseling
Description: Face-to-face and telephone counseling were applied to individuals in the intervention group.
Study: NCT01858038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fraxel Repair - Fractional Laser treatment
Description: An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
Study: NCT03538938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No SmokefreeTXT
Description: Proactive information about enrolling in adjunctive SmokefreeTXT text messaging support is not offered.
Study: NCT02123719

Intervention type: OTHER
Intervention: Surgery

Intervention type: OTHER
Intervention: Surgery
Study: NCT03538938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No SmokefreeTXT
Description: Proactive information about enrolling in adjunctive SmokefreeTXT text messaging support is not offered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No SmokefreeTXT
Description: Proactive information about enrolling in adjunctive SmokefreeTXT text messaging support is not offered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No SmokefreeTXT
Description: Proactive information about enrolling in adjunctive SmokefreeTXT text messaging support is not offered.
Study: NCT03414944

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SMART-Brain
Description: Prescription dose: Gross tumor (PGTV) 40-50 Gy/10 fractions/2 weeks + EBI (PCTV) 30 Gy/10 fractions/2 weeks.~OARs dose limits: Hippocampus D100%≤10Gy, Dmax≤17Gy,Inner ear: Dmean ≤15Gy.
Study: NCT01309412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: 5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
Study: NCT01844037

Intervention type: DEVICE
Group type: OTHER
Intervention: OneShot Ablation System
Description: Renal denervation